Vaxcyte (PCVX) Stock Forecast & Price Target

Vaxcyte is attractive because VAX-31’s OPUS-1 Phase 3 adult data delivered a clean sweep across all 32 prespecified co-primary endpoints, with non-inferiority versus PCV20 achieved across all 20 shared serotypes and 17 of 19 versus PCV21 under the stricter >0.667 threshold. The breadth of coverage, including superiority on the three unique VAX-31 serotypes and a favorable safety profile with no vaccine-related serious adverse events, strengthens the case that it can become a best-in-class pneumococcal vaccine and capture share in a market estimated above $8B. With ACIP expanding universal adult vaccination to >50 years old and BLA submission targeted for the first half of 2028 after OPUS-2 and OPUS-3 readouts expected in the first half of 2027, the company’s clinical and commercial de-risking path looks compelling.

Vaxcyte is facing an unfavorable fundamental setup because its vaccine pipeline remains clinical-stage, leaving safety, efficacy, and differentiation for VAX-31 and other candidates unproven against established competitors. The company’s DCF case relies on a 14.5% discount rate and 1.0% terminal growth, while revenues are only modeled across newborns, 50 to 64 year olds, and 65+ adults, underscoring how speculative the long-dated cash flows are. It also does not anticipate profitability for several years and may need additional capital, while commercialization would still require building infrastructure and overcoming guideline, regulatory, manufacturing, and competitive risks.